Opus Capital Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11K | Hold |
60,150
| – | – | ﹤0.01% | 147 |
|
|
2026
Q1 | $12K | Hold |
60,150
| – | – | ﹤0.01% | 136 |
|
|
2025
Q4 | $14K | Hold |
60,150
| – | – | ﹤0.01% | 134 |
|
|
2025
Q3 | $14K | Hold |
60,150
| – | – | ﹤0.01% | 134 |
|
|
2025
Q2 | $14K | Hold |
60,150
| – | – | ﹤0.01% | 123 |
|
|
2025
Q1 | $14K | Hold |
60,150
| – | – | ﹤0.01% | 121 |
|
|
2024
Q4 | $17K | Hold |
60,150
| – | – | ﹤0.01% | 116 |
|
|
2024
Q3 | $19K | Hold |
60,150
| – | – | ﹤0.01% | 120 |
|
|
2024
Q2 | $26K | Hold |
60,150
| – | – | ﹤0.01% | 117 |
|
|
2024
Q1 | $31K | Hold |
60,150
| – | – | ﹤0.01% | 121 |
|
|
2023
Q4 | $42K | Hold |
60,150
| – | – | 0.01% | 118 |
|
|
2023
Q3 | $55K | Hold |
60,150
| – | – | 0.01% | 112 |
|
|
2023
Q2 | $34K | Hold |
60,150
| – | – | 0.01% | 120 |
|
|
2023
Q1 | $38K | Hold |
60,150
| – | – | 0.01% | 118 |
|
|
2022
Q4 | $47K | Buy |
60,150
+5,000
| +9% | +$3.91K | 0.01% | 114 |
|
|
2022
Q3 | $39K | Hold |
55,150
| – | – | 0.01% | 106 |
|
|
2022
Q2 | $35K | Buy |
55,150
+10,000
| +22% | +$6.35K | 0.01% | 110 |
|
|
2022
Q1 | $31K | Hold |
45,150
| – | – | 0.01% | 109 |
|
|
2021
Q4 | $32K | Hold |
45,150
| – | – | 0.01% | 104 |
|
|
2021
Q3 | $58K | Hold |
45,150
| – | – | 0.01% | 98 |
|
|
2021
Q2 | $66K | Buy |
45,150
+650
| +1% | +$950 | 0.02% | 123 |
|
|
2021
Q1 | $66K | Hold |
44,500
| – | – | 0.02% | 125 |
|
|
2020
Q4 | $68K | Buy |
44,500
+19,500
| +78% | +$29.8K | 0.02% | 126 |
|
|
2020
Q3 | $19K | Buy |
25,000
+15,000
| +150% | +$11.4K | 0.01% | 117 |
|
|
2020
Q2 | $3K | Hold |
10,000
| – | – | ﹤0.01% | 113 |
|
|
2020
Q1 | $2K | Hold |
10,000
| – | – | ﹤0.01% | 104 |
|
|
2019
Q4 | $2K | Hold |
10,000
| – | – | ﹤0.01% | 161 |
|
|
2019
Q3 | $2K | Hold |
10,000
| – | – | ﹤0.01% | 145 |
|
|
2019
Q2 | $3K | Buy |
+10,000
| New | +$3K | ﹤0.01% | 166 |
|
Other funds holding NWBO
Opus Capital Group's NWBO Position: Q2 2026 in Review
Opus Capital Group held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q2 2026 at 60,150 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #147.
Opus Capital Group first reported a position in NWBO in Q2 2019 and has held it in 29 quarters since. The position peaked at $68K in Q4 2020. 2 funds tracked by Wall St. Rank hold NWBO as of Q2 2026.
- Opus Capital Group held 60,150 shares of Northwest Biotherapeutics, Inc. Common stock worth $11K as of Q2 2026.
- Opus Capital Group left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q2 2026.
- Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Opus Capital Group's portfolio in Q2 2026, its #147 holding.
- Opus Capital Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2019 and has held it in 29 quarters since.
- Opus Capital Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $68K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2026.
Based on Opus Capital Group's 13F filing for Q2 2026, filed 31 Jul 2026.